Proving the Economic
Value of Your Innovation
We are a team of academic and industry health economists and outcomes researchers providing high quality, high value real-world health economics and outcomes research consulting. READ MORE ABOUT US

Health Economics & Outcomes Research (HEOR)

We provide insights and analysis on potential market size and the design of rigorous economic evaluations, such as clinical studies and cost-effectiveness analysis.

Litigation Support & Policy Analysis (LSPA)

Our health economics methods support a wide range of healthcare litigation and health policy analyses, including expert services and testimony.

About

Health Economics & Outcomes Research

Led by Director and Principal Andrew Briggs, DPhil, and CEO John Schneider, PhD, AHE researchers and consultants have extensive knowledge and experience in the field of health economics and outcomes research (HEOR). These services include a wide variety of offerings across the product development continuum. In the early stages of development, we provide insights and analysis on potential market size and the design of rigorous economic evaluations, such as clinical studies and cost-effectiveness analysis.

About

Litigation Support & Policy Analysis (LSPA)

We bring rigorous health economics methodology to the complexities of health care litigation and policy analysis. Led by Director Cara Scheibling and CEO John Schneider, PhD, AHE researchers and consultants have extensive knowledge and experience providing health economics analysis, advice and testimony in support of a wide range of healthcare litigation and policy applications. Areas of expertise are listed below, and include substantial depth in a wide range of litigation, regulatory, and policy areas.

News

  • Online Simulation Model to Estimate the Total Costs of Tobacco Product Waste in Large U.S. Cities
    July 1, 2020
    Online Simulation Model to Estimate the Total Cost...
    Tobacco product waste (TPW) is one of the most ubiquitous forms of litter, accumulating in large amounts on streets, highways, sidewalks, beaches, parks, and other public places, and flowing into stor...

    CONTINUE READING...
  • Telehealth and Telemedicine in the Post-Pandemic Era
    June 18, 2020
    Telehealth and Telemedicine in the Post-Pandemic E...
    In many ways the arrival of the COVID-19 pandemic globally was met with sub-optimal levels of preparedness on the part of health care providers and provider systems, such as integrated delivery networ...

    CONTINUE READING...
  • Estimating QALY Losses Associates With Deaths in Hospital (COVID-19)
    May 15, 2020
    Moving Beyond 'Lives-Saved' From COVID-19
    This blog covers the presentation given as part of the ISPOR pre-conference plenary session on HEOR in the era of COVID-19 which was held on 14 May 2020.

    CONTINUE READING...
  • Economic Cycles and Product Development in Life Sciences
    May 11, 2020
    Economic Cycles and Product Development in Life Sc...
    Economic Cycles and Product Development in Life Sciences May 11, 2020 By John Schneider, PhD and Mirela Sima, MD, MBA The humanistic and economic consequences of the 2020 COVID-19 pandemic wi...

    CONTINUE READING...
  • Avalon’s Andrew Briggs Conducted Work on the Excess Mortality Attributable to COVID-19 Featured in the Wall Street Journal
    May 5, 2020
    Avalon’s Andrew Briggs Conducted Work on the Exces...
    The Wall Street Journal recently covered the work that Avalon’s Andrew Briggs conducted on the excess mortality attributable to COVID-19. Briggs put the U.S. average at almost 14 years lost and the U....

    CONTINUE READING...
  • Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department
    April 29, 2020
    Cost Impact Model of a Novel Multi-mRNA Host Respo...
    The Avalon team helped Inflammatix, Inc., develop economic evidence for HostDx Sepsis test for the diagnosis of acute infections. A newly released publication describes a cost impact model comparing t...

    CONTINUE READING...
  • Electronic Medical Records: Potential Issues in Litigation and Biomedical Research
    April 27, 2020
    Electronic Medical Records: Potential Issues in Li...
    In this blog entry we explore some of the potentially important issues surrounding the role of EMRs in litigation, where the discovery of medical documents and records increasing involves digitally st...

    CONTINUE READING...
  • Estimating QALY Losses Associates With Deaths in Hospital (COVID-19)
    April 17, 2020
    Estimating QALY Losses Associated With Deaths in H...
    Avalon Director Andrew Briggs, DPhil, addresses the issue of potential losses in quality-adjusted life years (QALYs) associated with COVID-19.

    CONTINUE READING...
  • Applications of HEOR Analytics: Covariate-Adjusted Analysis of Phase 3 Clinical Trial Data of Lenvatinib versus Sorafenib in Hepatocellular Carcinoma
    April 17, 2020
    Applications of HEOR Analytics: Covariate-Adjusted...
    In this blog entry we report on a good example of HEOR analytics: our recent study of covariate-adjusted analysis of trial data of lenvatinib versus sorafenib in hepatocellular carcinoma.

    CONTINUE READING...
  • COVID-19: Update on Epidemiology & Costs
    April 14, 2020
    COVID-19: Update on Epidemiology & Costs
    We define epidemiology broadly, including an up-to-date review of the key published medical literature on COVID-19. Following that, our discussion of costs focuses in part on the direct medical costs ...

    CONTINUE READING...
  • Distinguishing Between Viral and Bacterial Respiratory Infections
    April 8, 2020
    Distinguishing Between Viral and Bacterial Respira...
    Avalon researchers published important research on distinguishing between viral and bacterial respiratory infections, a topic that is of great importance given the COVID-19 pandemic. Check out the stu...

    CONTINUE READING...
  • March 13, 2020
    The Coronavirus: How Bad is it, Really?
    By: The Avalon Health Economics Team March 13, 2020 Within a few months we’ve gone from worrying about holiday shopping to worrying about global pandemics and watching the world shut down ar...

    CONTINUE READING...
  • February 10, 2020
    What is the Reasonable Value of Future Medical Car...
    Cara Scheibling and John Schneider, PhD February 7, 2020 A common challenge in economics and business is determining the fair-market value of products and services that have not yet “e...

    CONTINUE READING...
  • How Important is ICER Preparation and Review for U.S. Market Access?
    December 23, 2019
    How Important is ICER Preparation and Review for U...
    John Schneider, PhD and Alexis Doyle, MA Avalon Health Economics December 23, 2019 In recent years in the U.S., there has been an increase in the use of cost-effectiveness analysis (CEA) fo...

    CONTINUE READING...
  • Avalon Health Economics will be at ISPOR Copenhagen 2019
    October 16, 2019
    Avalon Health Economics Will Be At ISPOR Copenhage...
    Avalon Health Economics will be at ISPOR Copenhagen November 2nd-6th. Let us know if you will be there and want to set up a meeting! For more information, please visit the ISPOR website.

    CONTINUE READING...
  • September 16, 2019
    New HEOR Publication: Monitoring Technology for Se...
    Economic evaluation of passive monitoring technology for seniors 2019 By John E. Schneider,  Jacie Cooper. Cara Scheibling, and Anjani Parikh Abstract: By 2050, the global population of persons...

    CONTINUE READING...
  • August 27, 2019
    Avalon & Oberender Enter a New Collaboration
        Avalon Health Economics has entered into a collaborative agreement with Oberender, a leading global healthcare management consultancy based in Germany.  The agreement allows Av...

    CONTINUE READING...
  • July 17, 2019
    Using Payer Research to Assess Medical Device Mark...
      This blog is written by  John Schneider, PhD, Sabrina Chmelir, Jacie Cooper, and Shawn Davies, MA Advances in technological innovation and access to capital have recently resulted in a wave o...

    CONTINUE READING...
  • June 20, 2019
    Optometry’s Essential and Expanding Role in Health...
    This research summary is written by John E. Schneider, PhD & Cara M. Scheibling   A two-decade drumbeat of bold, future-focused and entirely bi-partisan changes in U.S. state laws has ush...

    CONTINUE READING...
  • June 19, 2019
    Healthcare Use Cases for Blockchain Technology
    This blog was written by John Schneider, PhD, Katherine Dick, Cara Scheibling Recently, the crypto-currency company Bitcoin has been in the news, mainly for its combination of volatility in valuation...

    CONTINUE READING...
  • June 10, 2019
    Smoke, Mirrors, and Wild Geese: What Should Be the...
      Andrew Briggs, DPhil Chair of Health Economics, University of Glasgow, Glasgow UK. Senior Scientist, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Director and Principa...

    CONTINUE READING...
  • March 14, 2019
    Avalon Health Economics will be at ISPOR New Orlea...
    Avalon Health Economics will be at ISPOR New Orleans, May 18 through May 22. We will be engaged in our usual array of posters, podium presentations, and short courses. If you are planning on attending...

    CONTINUE READING...
  • December 26, 2018
    Avalon Health Economics Collaborates with Acaster-...
    Avalon Health Economics is happy to announce an exciting new collaboration with the London-based Acaster-Lloyd Consulting, Ltd. Acaster-Lloyd, led by Sarah Acaster and Andrew Lloyd, is a leader in the...

    CONTINUE READING...
  • September 28, 2018
    Avalon Health Economics will be at ISPOR Barcelona...
    Avalon Health Economics will be at ISPOR Barcelona, Nov. 10 through Nov. 14.  We will be engaged in our usual array of posters, podium presentations, and short courses.  If you are planning on attendi...

    CONTINUE READING...
  • December 1, 2017
    Avalon CEO John Schneider will be speaking at the ...
    Avalon CEO John Schneider will be speaking at the 4th Annual Conference on Health Outcomes, Data Communications, Market Access and Value-Based Contracting in Philadelphia, January 22-24, 2018.

    CONTINUE READING...
  • October 1, 2017
    Avalon CEO John Schneider will be presenting on th...
    Avalon CEO John Schneider will be presenting on the panel of "Blockchain Use-Cases, Brainstorm: Replacing the Middleman: Healthcare, Retail, Finance and More" at the Blockchain Economic Forum 2017 in ...

    CONTINUE READING...
  • October 1, 2017
    Avalon Health Economics at the 20th Annual Europea...
    In our work in health economics and outcomes research (HEOR) for the life sciences, including biotechnology, pharmaceuticals, and medical devices, we must maintain close ties with our colleagues and s...

    CONTINUE READING...
  • April 1, 2017
    AHE Presents: Symposium on Emerging Trends in U.S....
    Avalon Health Economics Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access Tuesday, May 9th at the Hy...

    CONTINUE READING...
  • February 22, 2017
    The Value of Biopharmaceutical Innovation in the U...
    There have been some negative reports recently regarding the pricing practices of some pharmaceutical companies. However, it is important to give at least equal consideration to the value derived from...

    CONTINUE READING...
  • December 7, 2016
    The Evolving Landscape of U.S. Payer Coverage Deci...
    Although there are a large number of public and private payers in the U.S., medical device and pharmaceutical manufacturers generally focus on two types of payers: (1) Medicare, which is administered ...

    CONTINUE READING...

Contact Us

Have a question or interested in learning more? Contact us!

Do NOT follow this link or you will be banned from the site!